Chimeric antibodies for treatment of amyloid deposition diseases

Abstract

A chimeric mouse-human antibody for treatment of amyloid deposition diseases, pharmaceutical compositions comprising the antibody, methods and materials for producing the antibody, and methods for treating an amyloid deposition disease using the antibody and the pharmaceutical composition.

What is claimed is: 
     
         1 . A chimeric mouse-human antibody which comprises the V K  region of SEQ ID NO: 47 and the V H  region of SEQ ID NO: 48. 
     
     
         2 . The chimeric mouse-human antibody of  claim 1  which binds to an epitope expressed by the β-pleated sheet configuration of amyloid fibrils with higher affinity than the mouse antibody comprising the V K  region of SEQ ID NO: 36 and the V H  region of SEQ ID NO: 35. 
     
     
         3 . A pharmaceutical composition comprising the antibody of  claim 1  and a pharmaceutically acceptable carrier. 
     
     
         4 . A vector construct selected from the group consisting of 11-1F4VK.pKN100, 11-1F4VHpG1D200, and pG1KD200-11-1F4. 
     
     
         5 . The vector construct of  claim 4  which is 11-1F4VK.pKN100. 
     
     
         6 . The vector construct of  claim 4  which is 11-1F4VHpG1D200. 
     
     
         7 . The vector construct of claim  12  which is pG1KD200-11-1F4. 
     
     
         8 . A chimeric mouse-human antibody produced by a method comprising co-transfection in mammalian cells of vector constructs 11-1F4VK.pKN100 and 11-F4VH.pG1 D200. 
     
     
         9 . A chimeric mouse-human antibody produced by a method comprising co-transfection in mammalian cells of supervector construct pG1 KD200-11-1F4. 
     
     
         10 . A polypeptide selected from SEQ. ID NO: 47 and SEQ. ID NO: 48. 
     
     
         11 . A polynucleotide selected from SEQ. ID NO: 42 and SEQ ID NO: 45.